BioCatalystWatch
IFRXWorkspace / IFRX / OverviewCompany library
Price
Market cap
Next catalystExpected 1H 2027inf904 · Data readoutSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Other pipelines

izicopan

C5aR1

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

izicopan

C5aR1

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

izicopan

C5aR1

PreINDP1P3FilingApproved
Upcoming / outlook

  • Timing and evidence

izicopan

C5aR1

IFX-1 (vilobelimab)

C5a

IFX-1 (vilobelimab)

C5a

PreINDP1P2P3FilingApproved
IFX-1 (vilobelimab)

C5a

PreINDP1P2P3FilingApproved
IFX002

C5a

PreINDP1P2P3FilingApproved

Partner / License out

C5a

PreINDP1P2P3FilingApproved
Upcoming / outlook

Approved / commercial

GOHIBIC (vilobelimab)

C5a

PreINDP1P2P3FilingApproved
Upcoming / outlook

History / paused

izicopan

C5aR1

PreINDP1P3FilingApproved
Upcoming / outlook

izicopan

C5aR1

PreINDP1P2P3FilingApproved
Upcoming / outlook

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

IFRX PR & News

IFRX SEC archive